SEMINARS IN HUMAN AND TRANSLATIONAL IMMUNOLOGY

Presented by

Yale School of Medicine, Human and Translational Immunology Program

"Bile-derived organoids: A novel approach to Primary Sclerosing Cholangitis (PSC)"

David Assis, MD

Associate Professor of Medicine (Digestive Diseases); Director, Fellowship Program, Digestive Diseases
Yale School of Medicine

Tuesday, February 8, 2022 from 4-5 PM
Seminar by Zoom

CME Activity Code: Text 28998 to 203-442-9435

Host: Dr. Dan Jane-wit
Course Directors: Dr. Carrie Lucas and Dr. Ellen Foxman

There is no corporate support for this activity. This activity is not supported by any educational grants.
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT
The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will:
1. Understand the challenges and unmet needs in Primary Sclerosing Cholangitis (PSC).
2. Learn about the potential of 3D organoids from bile to better understand PSC pathophysiology.
3. Gain insight into the potential of organoids from patients with PSC to advance personalized therapeutic options.

FACULTY DISCLOSURES
David Assis: Received grant or research support from Gilead
Carrie Lucas: None
Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.